Therefore, targeting PDE4B could provide cardioprotection in patients with acute MI referred for reperfusion [92], and PDE4B inhibitors emerge as an appealing pharmacological therapy to ameliorate MI/R injury. The gene discussed is PDE4B; the disease is myocardial infarction.